Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-01-27
2009-11-24
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S331000, C423S405000, C435S370000
Reexamination Certificate
active
07622447
ABSTRACT:
There is provided a method of reducing insulin resistance in a mammalian patient comprising selecting a patient suffering from insulin resistance and administering a compound which increases hepatic glutathione and a compound which increases hepatic nitric oxide.
REFERENCES:
patent: 6436996 (2002-08-01), Vitek et al.
patent: WO 92/18002 (1992-10-01), None
patent: WO 00/07575 (2000-02-01), None
patent: WO 00/19992 (2000-04-01), None
patent: WO-00/19992 (2000-04-01), None
Stoyanovsky, et al., Cell Calcium, 1997, 21(1), 19-29.
[Retrived from]http://dictionary.cambridge.org/results.asp?dict=A&searchword=of, 2007, 1 page [retrived on Jul. 11, 2007].
Mattia, et al., Diabetologia, 1998, 41, 1392-1396.
Buckley, 2000, Am. J. Physiol. Cell Physiol, 279, C1168-C1176.
Corrales, 1999, Journal of Hepatology, 31, 887-894.
Mattia, 1998, Diabetooglia, 41, 1392-1396.
Kondo, 1997, FEBS Letters, 413, 236-238.
Mattia, 1998, Diabetologia, 41, 1392-1396.
Robak, 1995, Pol. J. Pharmacol., 47, 63-67.
Guarino et al., 2003, “Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action,”Am. J. Physiol Gastrointest Liver Physiol, vol. 284, pp. G588-G594.
Anderson, 1998, “Glutathione: an overview of biosynthesis and modulation,”Chemico-Biological Interactions111-112, pp. 1-14.
File History for US 6,436,996, 2002.
Czech et al., (1978) “Insulin Response in Skeletal Muscle and Fat Cells of the Genetically Obese Zucker Rat”,Metabolism, Vo. 27, No. 12, Suppl. 2 (Dec.) pp. 1967-1981.
De Mattia et al., (1998) “Influence of Reduced Glutathione Infusion of Glucose Metabolism in Patients With Non-Insulin-Dependent Diabetes Mellitus”,Metabolism, Vo. 47, No. 8 (Aug.) pp. 993-997.
Dowell et al., (1999) “Decreased basal despite enhanced agonist-stimulated effects of nitric oxide in 12-week-old stroke-prone spontaneously hypertensive rate”,European Journal of Pharmacology, 379: 175-182.
Khamaisi et al., (2000) “Effect of inhibition of glutathione synthesis on insulin action: in vivo and in vitro studies using buthionine sulfoximine”,Biochem. J., 349: 579-586.
Khamaisi et al., (1997) “Lipoic Acid Reduces Glycemia and Increases Muscle GLUT4 Content in Streptozotocin-Diabetic Rats”,Metabolism, Vo. 46, No. 7 (Jul.): pp. 763-768.
Lautt et al., (1998) “Rapid insulin sensitivity test (RIST)”,Can. J. Physiol. Pharmacol., 76: 1080-1086.
Lautt (1999) “The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetics”Can. J. Physiol. Pharmacol., 77: 553-562.
Marinho et al., (1997) “Glutathione metabolism in hepatomous liver of rats treated with diethylnitrosamine”,Biochimica et Biophysica Acta, 1360: 157-158.
Modan etal., (1985) “Hyperinsulinemia”,J. Clin. Invest., vol. 75, pp. 809-817.
Petrie et al., (1996) “Endothelial Nitric Oxide Production and Insulin Sensitivity”,Circulation, 93: 1331-1333.
Rett et al, (1996) “Alpha-Liponsaäure (Thioctsäure) steïgert die Insulinempfindlichkeit übergewichtiger Patienten mit Typ-II-Diabetes”,Diabetes Und Soffwechsel5, Supplement-Heft 3: 59-63.
Sadri et al., (1999) “Blockade of hepatic nitric oxide synthase causes insulin resistance”,Am. J. Physiol. 277: G101-G108.
Schrammel et l., (1998) “Activation of Soluble Guanylyl Cyclase by the Nitrovasodilator 3-Morpholinosydnonimine Involves Formation of S-Nitrosoglutathione”,Molecular Pharmacology, 54: 207-212.
Wang et al., (1998) “Evidence of nitric oxide, a flow-dependent factor, being a trigger of liver regeneration in rats”,Can. J. Physiol. Pharmacol. 76: 1072-1079.
Xie et al., (1996) “Insulin resistance of sketetal muscle produced by hepatic parasympathetic interruption”,Am. J. Physiol., 270: E858-E863.
Young et al. (1998) “Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle”,Biochem. J., 329: 73-79.
Lautt W. Wayne
Macedo Paula
DiaMedica Inc.
Dorn Brian R.
Gudibande Satyanarayana R
Kosar Andrew D
Merchant & Gould P.C.
LandOfFree
Use of glutathione synthesis stimulating compounds in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of glutathione synthesis stimulating compounds in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of glutathione synthesis stimulating compounds in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079174